Sovleplenib|CAS 1415792-84-5|DC Chemicals

Cas No.:	1415792-84-5
Chemical Name:	Sovleplenib
Synonyms:	Sovleplenib;9CL6353KHO;Pyrido[3,4-b]pyrazin-5-amine, 7-[4-[1-(methylsulfonyl)-4-piperidinyl]phenyl]-N-[(2S)-2-morpholinylmethyl]-;Sovleplenib [INN];GTPL11886;compound 225 [WO2012167733A1];(S)-7-(4-(1-(Methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido(4,3-b)pyrazin-5-amine;1415792-84-5;(S)-7-(4-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)PHENYL)-N-(MORPHOLIN-2-YLMETHYL)PYRIDO[3,4-B]PYRAZIN-5-AMINE;Sovleplenib [WHO-DD];HY-145598;MS-28979;Sovleplenib (USAN/INN);CS-0376654;SCHEMBL14242080;Spleen Tyrosine Kinase Inhibitor HMPL-523;EX-A7664;Syk Inhibitor HMPL-523;DA-67702;AKOS040752025;7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-N-[[(2S)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine;F78019;D12953;HMPL-523;compound 225 (WO2012167733A1);UNII-9CL6353KHO;HMPL-523 [WHO-DD];GLXC-27900;HMPL523
SMILES:	S(C)(N1CCC(C2C=CC(C3C=C4C(=C(N=3)NC[C@@H]3CNCCO3)N=CC=N4)=CC=2)CC1)(=O)=O
Formula:	C₂₄H₃₀N₆O₃S
M.Wt:	482.598403453827
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC48364	Sovleplenib	Sovleplenib is a highly potent inhibitor of spleen tyrosine kinase (Syk), derived from the innovative research disclosed in patent WO2012167733 A1. This compound demonstrates significant potential in modulating Syk-mediated signaling pathways, offering a promising therapeutic approach for conditions where Syk activity plays a critical role. Its development underscores the ongoing advancements in targeted kinase inhibition, providing a valuable tool for both research and potential clinical applications in immune-related and inflammatory diseases.
DC48025	Cevidoplenib dimesylate	Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities.
DC40848	SRX3207	SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses anti-tumor activity.
DC28254	Lanraplenib monosuccinate	Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.